Second Affiliated Hospital of Soochow University

Running trials

• Not yet recruiting

  Drug-coated Balloons Versus Drug-eluting Stents for the Treatment of Femoropopliteal In-Stent Restenosis

  NCT07277218· Chunshui He· Source

• Active, not recruiting

  A Pharmacokinetic Study of Budesonide Delayed Release Tablet D23A (D23) in Healthy Chinese Participants Under Fasting Conditions

  NCT07925216· Phase 1· Triastek, lnc.· Source

• Not yet recruiting

  A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants

  NCT07897240· Phase 1· Triastek, lnc.· Source

• Recruiting

  A Study of ATG-201 in Adult Participants With Autoimmune Diseases

  NCT07732309· Phase 1· Antengene Biologics Limited· Source

• Recruiting

  A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT07795346· Phase 3· Antengene Biologics Limited· Source

• Recruiting

  DEC003M in Prostate Cancer

  NCT07657806· Phase 1· Hangzhou DAC Biotechnology Co., Ltd.· Source

• Not yet recruiting

  Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease

  NCT07741045· Phase 3· Hangzhou PhecdaMed Co., Ltd.· Source

• Recruiting

  A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

  NCT07406035· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Recruiting

  Polypills Approach for Multiple Cardiovascular Risk Factors

  NCT07679828· China Medical University, China· Source

• Enrolling by invitation

  Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec

  NCT07658417· Novo Nordisk A/S· Source

• Recruiting

  A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

  NCT07564596· Phase 1/2· Climb Bio, Inc.· Source

• Recruiting

  Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer

  NCT07552402· Harbin Medical University· Source

• Not yet recruiting

  AI-Integrated Emotional Granularity Training for Resilience and Quality of Life in Colorectal Cancer Survivors

  NCT07611071· The Hong Kong Polytechnic University· Source

• Recruiting

  A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

  NCT07477587· Phase 1· Shanghai Henlius Biotech· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

  NCT07483073· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

  NCT07483099· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  NCT07409181· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

  NCT07355218· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  A Study of E6742 in Participants With Systemic Lupus Erythematosus

  NCT07515014· Phase 2· Eisai Co., Ltd.· Source

• Recruiting

  To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus

  NCT07447986· Phase 2· Hangzhou Sumgen Biotech Co., Ltd.· Source

• Recruiting

  Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial Stenosis

  NCT07932639· Phase 4· Second Affiliated Hospital of Soochow University· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT07327229· Phase 1/2· Antengene Biologics Limited· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  NCT07369011· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  NCT07353931· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated Pain

  NCT07318688· Phase 3· Hope Medicine (Nanjing) Co., Ltd· Source

• Not yet recruiting

  Left Ventricular Myocardial Work for Predicting Response to CRT

  NCT07319065· First Hospital of China Medical University· Source

• Not yet recruiting

  DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes

  NCT07241897· Phase 3· Second Affiliated Hospital of Soochow University· Source

• Recruiting

  Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)

  NCT07262645· Phase 3· Danyang Huichuang Medical Equipment Co., Ltd.· Source

• Recruiting

  A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors

  NCT07179679· Phase 1· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)

  NCT07805967· Second Affiliated Hospital of Soochow University· Source

• Recruiting

  BDB-001 Phase III Trial in ANCA-Associated Vasculitis

  NCT07168161· Phase 3· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

  NCT07202884· Phase 3· Eli Lilly and Company· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07169578· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease

  NCT07068438· Suzhou Hengruihongyuan Medical Technology Co. LTD· Source

• Recruiting

  Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke

  NCT07095790· Phase 4· Second Affiliated Hospital of Soochow University· Source

• Enrolling by invitation

  A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

  NCT07376629· Phase 2· Huabo Biopharm Co., Ltd.· Source

• Recruiting

  A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

  NCT07124936· Phase 1/2· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment

  NCT06922929· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source

• Not yet recruiting

  Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.

  NCT06922903· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source

• Active, not recruiting

  The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

  NCT06921486· Phase 2/3· Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

  NCT06878404· Phase 3· Janssen Research & Development, LLC· Source

Showing 50 of 89.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lupus (SLE)8 recruiting
• Crohn's disease6 recruiting
• Stroke5 recruiting
• Gastric and oesophageal cancer4 recruiting
• Parkinson disease4 recruiting
• Prostate cancer4 recruiting
• Diffuse large B-cell lymphoma3 recruiting
• Multiple myeloma3 recruiting
• Obesity3 recruiting
• Alzheimer disease2 recruiting
• Colorectal cancer2 recruiting
• Insomnia2 recruiting
• Lung cancer2 recruiting
• Type 2 diabetes2 recruiting
• Ulcerative colitis2 recruiting
• ANCA-associated vasculitis1 recruiting
• Bladder cancer1 recruiting
• Chronic kidney disease1 recruiting
• COPD1 recruiting
• Endometriosis1 recruiting
• Essential tremor1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• IgA nephropathy1 recruiting
• Lewy body dementia1 recruiting
• Liver and biliary tract cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple system atrophy1 recruiting
• Narcolepsy1 recruiting
• Obstructive sleep apnoea1 recruiting
• Osteoarthritis1 recruiting
• Osteoporosis1 recruiting
• Pancreatic cancer1 recruiting
• Peripheral artery disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Sjögren's disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thyroid cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection

  NCT07411755· Phase 1· Jiangsu Genscend Biopharmaceutical Co., Ltd· Source

• Completed

  Bioequivalence Study of GZR18 Injection Before and After CMC Change

  NCT07355738· Phase 1· Gan & Lee Pharmaceuticals.· Source

• Completed

  Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma

  NCT07807007· Phase 2· Shanghai Xin Huanghe Pharmaceutical Co., Ltd.· Source

• Completed

  How Emotional Granularity Helps Build Resilience in Young and Middle-Aged Colorectal Cancer Survivors

  NCT07200388· The Hong Kong Polytechnic University· Source

• Completed

  Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder

  NCT06975514· Phase 3· Shanghai Haiyan Pharmaceutical Technology Co., Ltd.· Source

• Completed

  A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury

  NCT06888115· Phase 1· Cascade Pharmaceuticals, Inc· Source

• Completed

  To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

  NCT06552520· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Completed

  Study on Mass Balance of [14C]HSK39297 in Healthy Chinese Adult Male Subjects

  NCT06852092· Phase 1· Haisco Pharmaceutical Group Co., Ltd.· Source

• Completed

  Observational Study of the Use of Extraneal in Peritoneal Dialysis in Patients

  NCT06492031· Vantive Health LLC· Source

• Completed

  A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.

  NCT07836140· Phase 2· Second Affiliated Hospital of Soochow University· Source

• Completed

  Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

  NCT06241313· Phase 3· AbbVie· Source

• Completed

  A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults

  NCT05989048· Phase 3· Pfizer· Source

• Terminated

  TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

  NCT06106841· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Completed

  A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

  NCT06068465· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source

• Completed

  A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

  NCT05810038· Phase 3· Pfizer· Source

• Completed

  A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis

  NCT05265325· Phase 2· Kind Pharmaceuticals LLC· Source

• Completed

  Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

  NCT05590793· Phase 3· Ipsen· Source

• Completed

  Repetitive Transcranial Magnetic Stimulation for Musculoskeletal Pain in Patients With Parkinson's Disease

  NCT05537597· Second Affiliated Hospital of Soochow University· Source

• Completed

  Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

  NCT05298423· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

  NCT05348785· Phase 2· Biogen· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Amgen· Source

• Recruiting

  JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  NCT04892173· Phase 3· Johnson & Johnson Enterprise Innovation Inc.· Source

• Completed

  Chinese Osteoporotic Fracture Registration Network Platform

  NCT05339425· Peking Union Medical College Hospital· Source

• Terminated

  Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04921358· Phase 3· BeiGene· Source

• Completed

  Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

  NCT04805307· Phase 1· Keymed Biosciences Co.Ltd· Source

• Completed

  Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT03358875· Phase 3· BeiGene· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Osteoporosis34 works · 2 trials
• Glioblastoma22 works · 0 trials
• Obstructive sleep apnoea18 works · 1 trial
• Multiple system atrophy4 works · 2 trials